Articles

Phase 2 data show that continuation of Bruton’s tyrosine kinase treatment with acalabrutinib may represent a viable treatment strategy in patients with CLL who have become intolerant to ibrutinib and whose disease has progressed. Read More ›

In a phase 1b study, the novel PI3kδ inhibitor ME-401 showed promising response rates with acceptable tolerability when evaluated in a flexible dosing schedule in follicular lymphoma. Additional studies are enrolling patients to further evaluate the clinical potential for this investigative therapy. Read More ›

A novel combination of venetoclax, atezolizumab, and obinutuzumab is being studied in patients with Richter transformation of CLL into diffuse large B-cell lymphoma. Read More ›

The combination of rituximab, lenalidomide, and ibrutinib as lead-in therapy prior to chemotherapy is effective in patients with newly diagnosed diffuse large B-cell lymphoma. Read More ›

In an ongoing phase 1/2 trial, the investigational CAR T therapy lisocabtagene maraleucel induced deep and durable responses, with many patients achieving minimal residual disease (MRD) status to date. Read More ›

Newly reported findings from the iNNOVATE study corroborate earlier reports that ibrutinib has a positive impact on patient-reported outcomes in Waldenström’s macroglobulinemia (WM). Read More ›

In a retrospective analysis, the doublet combination of rituximab plus bendamustine showed better response rates and event-free survival rates than 2 different triplet regimens when given as frontline treatment of Waldenström’s macroglobulinemia (WM). Read More ›

Newly reported findings from the iNNOVATE study corroborate earlier reports that ibrutinib has a positive impact on patient-reported outcomes in Waldenström’s macroglobulinemia. Read More ›

Tucatinib and neratinib show encouraging activity in patients with advanced breast cancer and central nervous system metastases. Read More ›

Alterations in CDK and PI3K pathways are frequent in breast cancer brain metastases; could targeting these genetic alterations lead to improved survival? Read More ›